Table I.
Baseline characteristics and treatment for all patients with a pre-treatment plasma EBV-DNA measurement and by plasma EBV status
| All N=61 |
pEBVd+ N=15 |
pEBVd− N=46 |
P-value | |
|---|---|---|---|---|
| Median age, years (range) |
62 (19–85) | 62 (38–82) | 62 (19–85) | 0.90 |
| Males, no. (%) | 40 (66) | 12 (80) | 28 (61) | 0.18 |
| PTCL Subtype, no. (%) | ||||
| PTCL-NOS | 28 (46) | 7 (47) | 21 (46) | 0.06 |
| AITL | 15 (25) | 7 (47) | 8 (17) | |
| ALCL ALK+ | 4 (6) | 1 (6) | 3 (6) | |
| ALCL ALK− | 10 (17) | 0 (0) | 10 (22) | |
| Others | 4 (6) | 0 (0) | 4 (9) | |
| Stage, no. (%) | ||||
| I/ II | 8 (13) | 0 (0) | 8 (17) | 0.18 |
| III/ IV | 53 (87) | 15 (100) | 38 (83) | |
| ECOG PS >1, no. (%) | ||||
| Yes | 21(38) | 6 (46) | 15 (36) | 0.53 |
| No | 34(62) | 7 (54) | 27 (64) | |
| Missing | 6 | 2 | 4 | |
| Elevated LDH, no. (%) | ||||
| Yes | 37 (63) | 8 (57) | 29 (64) | 0.62 |
| No | 22 (37) | 6 (43) | 16 (36) | |
| Missing | 2 | 1 | 1 | |
| BM Involved, no. (%) | ||||
| Yes | 16 (29) | 5 (45) | 11 (25) | 0.27 |
| No | 39 (71) | 6 (55) | 33 (75) | |
| Missing | 6 | 4 | 2 | |
| >1 Extranodal Sites, no. (%) |
||||
| Yes | 24 (39) | 9 (60) | 15 (33) | 0.06 |
| No | 37 (61) | 6 (40) | 31 (67) | |
| IPI1, no. (%) | ||||
| 0–2 | 22(42) | 2 (17) | 20 (49) | 0.09 |
| 3–5 | 31(58) | 10 (83) | 21 (51) | |
| Missing | 8 | 3 | 5 | |
| Induction Therapy, no. (%) |
||||
| CHOP | 21 (36) | 3 (21) | 18 (41) | 0.25 |
| EPOCH | 21 (36) | 7 (50) | 14 (32) | |
| Others | 12(21) | 2 (14) | 10 (23) | |
| No Treatment | 4 (7) | 2 (14) | 2 (5) | |
| Missing | 3 | 1 | 2 | |
AITL=angioimmunoblastic T-cell lymphoma, ALCL=anaplastic large cell lymphoma, ALK=anaplastic lymphoma kinase; PS=performance status; LDH=lactate dehydrogenase; BM=bone marrow;
1
IPI=International Prognostic Index, 1 point for age>60yo, PS>1, LDH elevated, >1 extranodal site, stage III/IV; pEBVd=plasma EBV-DNA, PTCL-NOS=peripheral T-cell lymphoma not otherwise specified,